Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03155945 | Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain | PHASE2 | COMPLETED | 14 | — | — | Jul 1, 2017 | Sep 1, 2018 | Nov 1, 2021 | - | — |
| Name | Type | Description |
|---|---|---|
| Olorinab | DRUG | Olorinab active treatment for 8 weeks. |